A Phase 2, Randomized, Double-Blind, Placebo-Controlled Parallel Group Study Of Vhb937 In Amyotrophic Lateral Sclerosis (Als) Over 40 Weeks Followed By An Open-Label Extension (Astrals)
Posted Date: Mar 5, 2025
- Investigator: Hani Kushlaf
- Specialties: Neurology, Neuromuscular Disorders
- Type of Study: Drug
The participants will be randomly allocated to either VHB937 or placebo treatment in a 2:1 randomization ratio. Treatment or placebo will be administered via i.v. (infusion) administered every 4 weeks and can be add-on to stable SoC treatment.
Criteria:
Patients Must Have A Diagnosis Of Sporadic Or Familial Als With Onset Of Als Symptoms Within 24 Months.
Keywords:
Als, Amyotrophic Lateral Sclerosis
For More Information:
Ashley Smith
5133746895
ashley.fisher@uc.edu